| Bioactivity | Litifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab can be used for cutaneous lupus erythematosus (CLE) study[1][2]. |
| Target | C-type lectin domain family 4 member C, CLEC4C |
| Name | Litifilimab |
| CAS | 2407378-48-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Cho SK, et al. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus. Expert Opin Investig Drugs. 2023 May;32(5):345-353. [2]. Litifilimab. IMGT/mAb-DB. |